Clinical stage development of anti-inflammatory antibody therapeutics for treatment of immunovascular disease Athera is a clinical stage biopharmaceutical company focused on developing targeted anti-inflammatory biological candidate drugs for the prevention and treatment of immunovascular disease. The Company initiated its current program in 2005, harnessing breakthrough innovations made at the world-renowned Karolinska Institutet, Sweden. The company currently has a proprietary clinical development stage program, PC-mAb, supported by a proprietary diagnostic kit. The development of the antibody therapy haves in part been co-financed by the EU FP7 program, in the project CARDIMMUN. Athera is located in Stockholm at Hagastaden, next the new Karolinska Hospital, and at AZ BioVentureHub, the incubator established at the Astra Zeneca facility in Gothenburg as an innovative ecosystem to further strengthen the life science industry in Scandinavia.